Publications by authors named "Hanrong Feng"

Article Synopsis
  • KRAS inhibitors are medicine that work against a type of pancreatic cancer called PDAC, but patients often develop resistance to these treatments.
  • When patients with a specific mutation (KRASG12C) took certain drugs, new mutations and changes were found that helped the cancer resist the treatment.
  • Using a mix of KRAS inhibitors and chemotherapy showed better results in controlling tumors in mouse models, suggesting that combining treatments might be a smarter approach for patients.
View Article and Find Full Text PDF

Purpose: Combining gemcitabine with CHK1 inhibition has shown promise in preclinical models of pancreatic ductal adenocarcinoma (PDAC). Here, we report the findings from a phase I expansion cohort study (NCT02632448) investigating low-dose gemcitabine combined with the CHK1 inhibitor LY2880070 in patients with previously treated advanced PDAC.

Patients And Methods: Patients with metastatic PDAC were treated with gemcitabine intravenously at 100 mg/m2 on days 1, 8, and 15, and LY2880070 50 mg orally twice daily on days 2-6, 9-13, and 16-20 of each 21-day cycle.

View Article and Find Full Text PDF

A critical determinant of DNA repair pathway choice is REV7, an adaptor that binds to various DNA repair proteins through its C-terminal seatbelt domain. The REV7 seatbelt binds to either REV3, activating translesion synthesis, or to SHLD3, activating non-homologous end joining (NHEJ) repair. Recent studies have identified another REV7 seatbelt-binding protein, CHAMP1 (chromosome alignment-maintaining phosphoprotein 1), though its possible role in DNA repair is unknown.

View Article and Find Full Text PDF

The Plk1-interacting checkpoint helicase (PICH) protein localizes to ultrafine anaphase DNA bridges in mitosis along with a complex of DNA repair proteins. Previous studies show PICH deficiency-induced embryonic lethality in mice. However, the function of PICH that is required to suppress embryonic lethality in PICH-deficient mammals remains to be determined.

View Article and Find Full Text PDF
Article Synopsis
  • New drugs called KRAS inhibitors, like adagrasib and sotorasib, help treat some cancers but sometimes stop working because the cancer cells become resistant.
  • In a study with 38 patients, researchers found that almost half had changes in their cancer cells that allowed them to resist the treatment, with some having more than one change.
  • The study shows that we need better strategies to deal with this resistance to continue helping cancer patients effectively.
View Article and Find Full Text PDF

Several studies have reported that gut and lung microbiomes are involved in the process of asthma pathogenesis. However, it remains unclear how perinatal or early-life antibiotic intervention affect adult allergic airway inflammation. We assigned C57BL/6 mice randomly to four experimental groups: normal saline control (NS), ovalbumin (OVA), vancomycin pretreated NS (VAN-NS), and vancomycin pretreated OVA (VAN-OVA).

View Article and Find Full Text PDF

Oleandrin is a monomeric compound extracted from leaves and seeds of Nerium oleander. It had been reported that oleandrin could effectively inhibit the growth of human cancer cells. However, the specific mechanisms of the oleandrin-induced anti-tumor effects remain largely unclear.

View Article and Find Full Text PDF